Northern Trust’s GT Biopharma GTBP Stock Holding History

Northern Trust’s Portfolio GTBP Stock Details GTBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$37K	Buy	+3,018	New	+$30.6K	﹤0.01%	4312
2024 Q1	–	Sell	-43	Closed	-$8.25K	–	4447
2023 Q4	$8.25K	Hold	43	–	–	﹤0.01%	4430
2023 Q3	$7.8K	Hold	43	–	–	﹤0.01%	4413
2023 Q2	$10.1K	Hold	43	–	–	﹤0.01%	4477
2023 Q1	$17.8K	Sell	43 -1	-2%	-$573	﹤0.01%	4469
2022 Q4	$29.2K	Hold	44	–	–	﹤0.01%	4402
2022 Q3	$58K	Sell	44 -8	-15%	-$15.3K	﹤0.01%	4286
2022 Q2	$118K	Sell	52 -166	-76%	-$315K	﹤0.01%	4104
2022 Q1	$472K	Sell	218 -9	-4%	-$19.8K	﹤0.01%	3762
2021 Q4	$520K	Buy	227 +4	+2%	+$15K	﹤0.01%	3793
2021 Q3	$1.13M	Sell	223 -78	-26%	-$587K	﹤0.01%	3513
2021 Q2	$3.5M	Buy	301 +255	+554%	+$2.65M	﹤0.01%	3052
2021 Q1	$235K	Buy	+46	New	+$201K	﹤0.01%	4056

Other funds holding GTBP

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

HRT Financial New York $57.2B AUM 52.85% 1-Year Est. Return

Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return

Arax Advisory Partners Denver, Colorado $17.7B AUM 20.22% 1-Year Est. Return

Opal Wealth Advisors Jericho, New York $479M AUM 15.43% 1-Year Est. Return

49 Wealth Management Austin, Texas $1.66B AUM 9.74% 1-Year Est. Return

Alongside Austin, Texas $904M AUM

Cetera Investment Advisers Schaumburg, Illinois $115B AUM 18.52% 1-Year Est. Return

Northern Trust's GTBP Position: Q2 2026 in Review

Northern Trust opened a new position in GT Biopharma (GTBP) in Q2 2026: 3,018 shares worth $37K. The stake represents ﹤0.01% of the portfolio and ranks #4312 among its holdings. This is a return to the name: Northern Trust previously reported a position in GTBP as recently as Q4 2023.

Northern Trust first reported a position in GTBP in Q1 2021 and has held it in 13 quarters since. The position peaked at $3.5M in Q2 2021. 55 funds tracked by Wall St. Rank hold GTBP as of Q2 2026.

Northern Trust held 3,018 shares of GT Biopharma worth $37K as of Q2 2026.
GT Biopharma was a new Northern Trust position in Q2 2026.
GT Biopharma made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #4312 holding.
Northern Trust first reported a position in GT Biopharma in Q1 2021 and has held it in 13 quarters since.
Northern Trust's GT Biopharma position peaked at $3.5M in Q2 2021.
55 funds tracked by Wall St. Rank held GT Biopharma as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.